Trial Profile
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atuliflapon (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 20 Oct 2016 Status changed from active, no longer recruiting to completed.